Back to News
Market Impact: 0.1
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Source: GlobeNewswire
Healthcare & BiotechManagement & Governance
A former senior Biogen and Roche executive is highlighted for experience in Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy. The text provides no company, role, transaction or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
BIIB0.10
ROP0.10
More News
- Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
- Genmab: Epkinly Shines In Phase 3 DLBCL Trial
- Paramount's hard-fought takeover of Warner Bros. Discovery closes Tuesday. Here's how we got here
- CNN, CBS News now under one roof as Paramount-Warner Bros merger closes
- Paramount Closes Warner Merger in Historic Hollywood Deal
- Skydance will combine HBO Max and Paramount+ into a single streaming service
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Software for Buy-Side Teams: Build the Research Stack
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit